TaiMed Biologics Inc.

Quick facts

Phase 3 pipeline

• ibalizumab-uiyk · Infectious Disease
  Ibalizumab-uiyk is a monoclonal antibody that binds to the CD4 receptor on T cells, preventing HIV entry and replication.

Phase 2 pipeline

• TMB-365
• TMB-380

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• TaiMed Biologics Inc. portfolio CI brief
• TaiMed Biologics Inc. pipeline updates RSS